| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Steffen Runge, Susann Schimmer, Jan Oschmann, Christine Bruun Schiødt, Sanne Möller Knudsen, Claus Bekker Jeppesen, Kjeld Madsen, Jesper Lau, Henning Thøgersen, Rainer Rudolp. Differential structural properties of GLP-1 and exendin-4 determine their relative affinity for the GLP-1 receptor N-terminal extracellular domain. Biochemistry. vol 46. issue 19. 2007-06-13. PMID:17444618. |
they bind and activate the pancreatic glp-1 receptor (glp-1r) with similar affinity and potency and thereby promote insulin secretion in a glucose-dependent manner. |
2007-06-13 |
2023-08-12 |
Not clear |
| Nicola Pannacciulli, Duc Son N T Le, Arline D Salbe, Kewei Chen, Eric M Reiman, Pietro A Tataranni, Jonathan Krakof. Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans. NeuroImage. vol 35. issue 2. 2007-06-04. PMID:17317222. |
outcome measures included changes in pet-measured regional cerebral blood flow (rcbf) and plasma concentrations of glp-1, glucose, insulin, and free-fatty acids (ffa), elicited by the administration of a satiating amount of a liquid formula meal. |
2007-06-04 |
2023-08-12 |
human |
| Nicola Pannacciulli, Duc Son N T Le, Arline D Salbe, Kewei Chen, Eric M Reiman, Pietro A Tataranni, Jonathan Krakof. Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans. NeuroImage. vol 35. issue 2. 2007-06-04. PMID:17317222. |
the peak postprandial increases in plasma glp-1 concentrations were correlated with increases in rcbf in the left dorsolateral prefrontal cortex (including the left middle and inferior frontal gyri), previously implicated in pet studies of human satiation, and the hypothalamus, previously implicated in the regulation of food intake in animal and human studies, both before and after adjustment for sex, age, body fat, and changes in plasma glucose, insulin, and serum ffa concentrations. |
2007-06-04 |
2023-08-12 |
human |
| Cheol Whee Park, Hyeong Wook Kim, Seung Hyun Ko, Ji Hee Lim, Gyeong Ryul Ryu, Hyun Wha Chung, Sang Woo Han, Seog Jun Shin, Byung Kee Bang, Matthew D Breyer, Yoon Sik Chan. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. Journal of the American Society of Nephrology : JASN. vol 18. issue 4. 2007-05-31. PMID:17360951. |
glucagon-like peptide-1 (glp-1) is a gut incretin hormone and is a new clinically available class of agents for improving of insulin resistance in both animals and humans with type 2 diabetes. |
2007-05-31 |
2023-08-12 |
mouse |
| Bernardo L Wajchenber. beta-cell failure in diabetes and preservation by clinical treatment. Endocrine reviews. vol 28. issue 2. 2007-05-23. PMID:17353295. |
the acute effect of glp-1 and glp-1 receptor agonists on beta-cells is stimulation of glucose-dependent insulin release, followed by enhancement of insulin biosynthesis and stimulation of insulin gene transcription. |
2007-05-23 |
2023-08-12 |
human |
| Jiaqi Chen, Gang Bai, Yang Yang, Peng Geng, Yu Cao, Yuanyuan Zh. Identifying glucagon-like peptide-1 mimetics using a novel functional reporter gene high-throughput screening assay. Peptides. vol 28. issue 4. 2007-05-21. PMID:17267075. |
glucagon-like peptide-1 (glp-1) stimulates insulin and inhibits glucagon secretion and therefore could potentially be used to treat diabetes type ii. |
2007-05-21 |
2023-08-12 |
mouse |
| Reawika Chaikomin, Keng Liang Wu, Selena Doran, Karen L Jones, Andre J P M Smout, Willem Renooij, Richard H Holloway, James H Meyer, Michael Horowitz, Christopher K Rayne. Concurrent duodenal manometric and impedance recording to evaluate the effects of hyoscine on motility and flow events, glucose absorption, and incretin release. American journal of physiology. Gastrointestinal and liver physiology. vol 292. issue 4. 2007-05-17. PMID:17204542. |
concurrently, glucose and 3-o-methylglucose (3-omg) were infused into the proximal duodenum (3 kcal/min), with frequent blood sampling to measure glucose, 3-omg, insulin, glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip). |
2007-05-17 |
2023-08-12 |
human |
| Reawika Chaikomin, Keng Liang Wu, Selena Doran, Karen L Jones, Andre J P M Smout, Willem Renooij, Richard H Holloway, James H Meyer, Michael Horowitz, Christopher K Rayne. Concurrent duodenal manometric and impedance recording to evaluate the effects of hyoscine on motility and flow events, glucose absorption, and incretin release. American journal of physiology. Gastrointestinal and liver physiology. vol 292. issue 4. 2007-05-17. PMID:17204542. |
overall, blood glucose (p<0.01) and plasma 3-omg concentrations (p<0.05) were lower during hyoscine than saline, whereas plasma insulin, glp-1, and gip concentrations were initially (t=20 min) lower during hyoscine (p<0.05). |
2007-05-17 |
2023-08-12 |
human |
| Máire E Doyle, Josephine M Ega. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacology & therapeutics. vol 113. issue 3. 2007-05-15. PMID:17306374. |
its particular effects on insulin and glucagon secretion have generated a flurry of research activity over the past 20 years culminating in a naturally occurring glp-1 receptor (glp-1r) agonist, exendin 4 (ex-4), now being used to treat type 2 diabetes mellitus (t2dm). |
2007-05-15 |
2023-08-12 |
Not clear |
| Máire E Doyle, Josephine M Ega. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacology & therapeutics. vol 113. issue 3. 2007-05-15. PMID:17306374. |
the most widely studied cell activated by glp-1 is the insulin-secreting beta cell where its defining action is augmentation of glucose-induced insulin secretion. |
2007-05-15 |
2023-08-12 |
Not clear |
| G Charpentier, D Dardari, J P Rivelin. How should postprandial glycemia be treated? Diabetes & metabolism. vol 32 Spec No2. 2007-05-14. PMID:17375403. |
at this stage, rather than overtreating high fasting blood glucose concentrations, systematic ppg exploration should be the rule so as to better define ppg treatment: the advantages of alpha-glucosidase inhibitors and the role of glp-1 analogs should be defined, the use of a rapid-acting insulin analog before the meal causing the highest postprandial blood glucose excursions, even systematically at all three meals, should be considered, or inhaled insulin. |
2007-05-14 |
2023-08-12 |
Not clear |
| Baptist Gallwit. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes. Drugs of today (Barcelona, Spain : 1998). vol 43. issue 1. 2007-05-01. PMID:17315049. |
glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic peptide (gip) are important incretin hormones contributing to 50-70% of the stimulation of insulin secretion after a meal. |
2007-05-01 |
2023-08-12 |
Not clear |
| P H L M Geelhoed-Duijvestij. Incretins: a new treatment option for type 2 diabetes? The Netherlands journal of medicine. vol 65. issue 2. 2007-05-01. PMID:17379930. |
glp-1 stimulates the production and secretion of insulin, the release of somatostatin, glucose utilisation by increasing insulin sensitivity and in animal studies also beta-cell function and expansion (proliferation). |
2007-05-01 |
2023-08-12 |
Not clear |
| Thomas Reinehr, Gideon de Sousa, Christian L Rot. Fasting glucagon-like peptide-1 and its relation to insulin in obese children before and after weight loss. Journal of pediatric gastroenterology and nutrition. vol 44. issue 5. 2007-05-01. PMID:17460495. |
to study the relationships between glucagon-like peptide-1 (glp-1), weight status, insulin, and insulin resistance in the fasting state. |
2007-05-01 |
2023-08-12 |
Not clear |
| Chien Li, Peilin Chen, Joan Vaughan, Kuo-Fen Lee, Wylie Val. Urocortin 3 regulates glucose-stimulated insulin secretion and energy homeostasis. Proceedings of the National Academy of Sciences of the United States of America. vol 104. issue 10. 2007-04-24. PMID:17360501. |
secretion of ucn 3-like immunoreactivity from cultured beta cells was stimulated by high glucose and insulin secretagogs such as glp-1; furthermore, 5 pancreatic ucn 3 mrna levels in vivo were increased during the positive energy balance caused by high-fat diet and by the absence of leptin. |
2007-04-24 |
2023-08-12 |
mouse |
| Thomas H Claus, Clark Q Pan, Joanne M Buxton, Ling Yang, Jennifer C Reynolds, Nicole Barucci, Michael Burns, Astrid A Ortiz, Steve Roczniak, James N Livingston, Kevin B Clairmont, James P Whela. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes. The Journal of endocrinology. vol 192. issue 2. 2007-04-12. PMID:17283237. |
glucagon-like peptide-1 (glp-1) promotes glucose-dependent insulin secretion from the pancreas, while glucagon promotes glucose output from the liver. |
2007-04-12 |
2023-08-12 |
mouse |
| Thomas H Claus, Clark Q Pan, Joanne M Buxton, Ling Yang, Jennifer C Reynolds, Nicole Barucci, Michael Burns, Astrid A Ortiz, Steve Roczniak, James N Livingston, Kevin B Clairmont, James P Whela. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes. The Journal of endocrinology. vol 192. issue 2. 2007-04-12. PMID:17283237. |
pegylated dapd (peg-dapd) increases insulin and decreases glucose in a glucose tolerance test, evidence of glp-1 receptor agonism. |
2007-04-12 |
2023-08-12 |
mouse |
| H Reuter, E Erdman. [Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus]. Deutsche medizinische Wochenschrift (1946). vol 132. issue 11. 2007-04-10. PMID:17342635. |
the incretin hormone glucagon-like peptide 1 (glp-1) is being synthesized from l-cells in the gut and enhances glucose-induced insulin secretion. |
2007-04-10 |
2023-08-12 |
Not clear |
| H Reuter, E Erdman. [Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus]. Deutsche medizinische Wochenschrift (1946). vol 132. issue 11. 2007-04-10. PMID:17342635. |
novel aspects in the treatment of type 2 diabetes by glp-1 receptor stimulation further include its influence on the insulin secretory pattern, insulin/glucagon ratio, body weight and possibly even pancreatic beta cell mass. |
2007-04-10 |
2023-08-12 |
Not clear |
| Jocelyn de Heer, Jens J Hols. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes. vol 56. issue 2. 2007-04-09. PMID:17259389. |
at 3 mmol/l glucose, glp-1 alone did not augment insulin secretion, whereas tolbutamide alone caused a rapid increase in insulin secretion. |
2007-04-09 |
2023-08-12 |
rat |